Developing new drugs to help with weight loss and metabolic disorders
Official title: New Generation of Mitochondrial Uncouplers for the Treatment of Metabolic DIsorders
Funded at Equator Therapeutics, INC. · NIH-10922344 · Data updated 2026-11-12
This study is testing a new drug that helps your body burn more energy to support weight loss and improve health for people dealing with obesity and related issues.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Equator Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Saint Louis, UNITED STATES) |
| Project start | September 20, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,571,137 |
| NIH project number | 2R44DK127880-02A1 |
| Project ID | NIH-10922344 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are struggling with obesity or related metabolic disorders.
✕Less likely to help
Patients who are not overweight or do not have metabolic disorders may not receive any benefit from this research.
What this research studies
This research focuses on creating a novel drug that enhances energy expenditure to aid in weight loss and combat obesity-related metabolic disorders. The approach involves targeting mitochondrial uncoupling proteins, which play a crucial role in regulating energy use in the body. By activating these proteins, the drug aims to increase the body's ability to burn fat without negatively affecting other vital processes. Patients may benefit from a new treatment option that complements existing therapies for obesity and metabolic conditions.
Why it matters
Potential benefit: If successful, this research could provide patients with a new treatment option that effectively aids in weight loss and improves metabolic health.
How similar studies have gone: Previous research has shown promise in targeting mitochondrial uncoupling proteins for weight management, indicating potential success for this novel approach.
Where this research is happening
-
Equator Therapeutics, INC.
Saint Louis, United States Active
Researchers
- Principal investigator: Vu, Simon — Equator Therapeutics, INC.
- Study coordinator: Vu, Simon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.